Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets

For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasi, Pashtoon M., Litzow, Mark R., Patnaik, Mrinal M., Hashmi, Shahrukh K., Gangat, Naseema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726703/
https://www.ncbi.nlm.nih.gov/pubmed/26904404
http://dx.doi.org/10.1016/j.lrr.2016.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726703/
https://www.ncbi.nlm.nih.gov/pubmed/26904404
http://dx.doi.org/10.1016/j.lrr.2016.01.002

Ejemplares similares